F-18 pylarify pharmaceutical
Active Awarded Last action
- Contract number
- 36C25026N0531
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $558,691
Award facts
- Contract value 100% obligated
- $558,691.12 Current and potential, with all options
- Completion date 71% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $558,691.12 firm fixed-price delivery order by Veterans Integrated Service Network 10 on May 1, 2026, for the supply of F-18 PYLARIFY (piflufolastat F-18) radiopharmaceutical products. The contract, which carries no set-aside designation, is scheduled for completion by December 31, 2026, with performance occurring at the contractor's facility in North Billerica, Massachusetts. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master contract vehicle that establishes the pricing and terms for pharmaceutical procurement across federal healthcare providers.
PYLARIFY is a specialized diagnostic imaging agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer, providing critical diagnostic capabilities for Veterans Affairs medical centers. Progenics Pharmaceuticals has established itself as a primary supplier of this radiopharmaceutical to the VA system, holding multiple blanket purchase agreements and indefinite delivery contracts with various Veterans Integrated Service Networks, as well as serving the Defense Health Agency and National Institutes of Health. The company's extensive federal contracting history demonstrates sustained demand for this specialized nuclear medicine product across the veteran healthcare system and military medical treatment facilities.
Quick answers
Who was awarded contract 36C25026N0531?
36C25026N0531 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on May 1, 2026.
How much is contract 36C25026N0531 worth?
The government has obligated $558,691 on 36C25026N0531.
Is contract 36C25026N0531 an order under another contract?
Yes. 36C25026N0531 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25026N0531 competed?
The extent of competition for 36C25026N0531 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award